Contributions
Abstract: EP1446
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Objectives: The objectives of this study were to study the prevalence and characteristics of headache in patients with multiple sclerosis (MS) and to clarify the relationship between headache and MS treatment.
Method: 782 MS patients were consecutively admitted. All patients filled out a detailed headache questionnaire and 754 patients were included.
Results: Of 754 patients, 515 (68.3%) reported having headache. According to the International Headache Society (IHS) criteria, we detected 202 (39%) suffering from migraine, 103 (20%) suffering from tension-type headache (TTH) and 198 (38%) with medication overuse headache (MOH). Twelve patients (2%) had unclassified headache. Three hundred and seventy seven patients (73%) were treated with immunomodulators (interferon beta/ glatiramer acetate), 81 (16%) with fingolimod, 35 (7%) with teriflunamide and 22 (4%) with natalizumab, respectively. One hundred and one (20%) reported that onset of headache occured prior to onset of MS spesific treatment, while 414 (80%) had headaches occured after therapy. A higher incidence of headache was found in patients treated with immunomodulators. Three hundred and twenty two (62%) patients have never sought help from a physician despite the severity and frequency of headache.
Conclusion: In our study, the prevalence of headache MS patients was 68%. The results of this study indicate a possible relationship may exist between headache and MS. Interestingly, MOH was far more prevalent in MS patients than in previously reported community populations.
Disclosure: nothing to disclose
Abstract: EP1446
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Objectives: The objectives of this study were to study the prevalence and characteristics of headache in patients with multiple sclerosis (MS) and to clarify the relationship between headache and MS treatment.
Method: 782 MS patients were consecutively admitted. All patients filled out a detailed headache questionnaire and 754 patients were included.
Results: Of 754 patients, 515 (68.3%) reported having headache. According to the International Headache Society (IHS) criteria, we detected 202 (39%) suffering from migraine, 103 (20%) suffering from tension-type headache (TTH) and 198 (38%) with medication overuse headache (MOH). Twelve patients (2%) had unclassified headache. Three hundred and seventy seven patients (73%) were treated with immunomodulators (interferon beta/ glatiramer acetate), 81 (16%) with fingolimod, 35 (7%) with teriflunamide and 22 (4%) with natalizumab, respectively. One hundred and one (20%) reported that onset of headache occured prior to onset of MS spesific treatment, while 414 (80%) had headaches occured after therapy. A higher incidence of headache was found in patients treated with immunomodulators. Three hundred and twenty two (62%) patients have never sought help from a physician despite the severity and frequency of headache.
Conclusion: In our study, the prevalence of headache MS patients was 68%. The results of this study indicate a possible relationship may exist between headache and MS. Interestingly, MOH was far more prevalent in MS patients than in previously reported community populations.
Disclosure: nothing to disclose